0001179110-13-011897.txt : 20130718
0001179110-13-011897.hdr.sgml : 20130718
20130718134702
ACCESSION NUMBER: 0001179110-13-011897
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130718
FILED AS OF DATE: 20130718
DATE AS OF CHANGE: 20130718
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Omthera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001477598
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263797738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 707 STATE ROAD
CITY: NEW JERSEY
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 908-741-4323
MAIL ADDRESS:
STREET 1: 707 STATE ROAD
CITY: NEW JERSEY
STATE: NJ
ZIP: 08540
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sofinnova Partners SAS
CENTRAL INDEX KEY: 0001574139
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35869
FILM NUMBER: 13974545
BUSINESS ADDRESS:
STREET 1: 17 RUE DE SERENE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33 1 53 05 41 13
MAIL ADDRESS:
STREET 1: 17 RUE DE SERENE
CITY: PARIS
STATE: I0
ZIP: 75008
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SOFINNOVA CAPITAL VI FCPR
CENTRAL INDEX KEY: 0001441261
STATE OF INCORPORATION: XX
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35869
FILM NUMBER: 13974546
BUSINESS ADDRESS:
STREET 1: C/O SOFINNOVA PARTNERS
STREET 2: 17 RUE DE SURENE
CITY: PARIS
STATE: XX
ZIP: 75008
BUSINESS PHONE: 33 1 53 054100
MAIL ADDRESS:
STREET 1: C/O SOFINNOVA PARTNERS
STREET 2: 17 RUE DE SURENE
CITY: PARIS
STATE: XX
ZIP: 75008
4
1
edgar.xml
FORM 4 -
X0306
4
2013-07-18
1
0001477598
Omthera Pharmaceuticals, Inc.
OMTH
0001441261
SOFINNOVA CAPITAL VI FCPR
17, RUE DE SERENE
PARIS
I0
75008
FRANCE
1
0
1
1
Director by Deputization
0001574139
Sofinnova Partners SAS
17, RUE DE SERENE
PARIS
I0
75008
FRANCE
1
0
1
1
Director by Deputization
Common Stock
2013-07-18
4
D
0
7159317
D
0
D
Graziano Seghezzi serves as a representative of Sofinnova VI FCPR and its affiliates on the board of directors of Omthera Pharmaceuticals, Inc. (the "Company") as a director by deputization.
Pursuant to the Agreement and Plan of Merger by and among the Company, Zeneca, Inc. and KAFA Acquisition Corp., dated May 27, 2013, each share of the Company's common stock was exchanged for $12.70 in cash, without interest, less any applicable withholding taxes, plus one contractual contingent value right, which represents the right to receive contingent payments of up to approximately $4.70 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods.
Sofinnova Partners SAS is the managing company of Sofinnova Capital VI FCPR and disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any.
/s/Christian S. Schade, Attorney-in-Fact
2013-07-18
/s/Christian S. Schade, Attorney-in-Fact
2013-07-18